相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B cells in systemic lupus erythematosus
Franziska Szelinski et al.
CURRENT OPINION IN RHEUMATOLOGY (2022)
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
Agner R. Parra Sanchez et al.
NATURE REVIEWS RHEUMATOLOGY (2022)
Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?
Ioannis Parodis et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M. Vital et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Sharzad Emamikia et al.
RHEUMATOLOGY (2022)
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
Ellen Ginzler et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
Vibeke Strand et al.
Lancet Rheumatology (2022)
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
Alexander Borg et al.
RHEUMATOLOGY (2021)
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
W. Winn Chatham et al.
ARTHRITIS & RHEUMATOLOGY (2021)
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
Julius Lindblom et al.
RHEUMATOLOGY (2021)
What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Global epidemiology of systemic lupus erythematosus
Megan R. W. Barber et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
Toni Maslen et al.
LUPUS SCIENCE & MEDICINE (2021)
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline
Kalliopi Klavdianou et al.
BIODRUGS (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
Mariele Gatto et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
Hermine Brunner et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
Ioannis Parodis et al.
FRONTIERS IN MEDICINE (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Christopher E. Collins et al.
RHEUMATOLOGY AND THERAPY (2020)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies
Andreas Schwarting et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With SystemicLupus Erythematosus
Ioannis Parodis et al.
ARTHRITIS CARE & RESEARCH (2019)
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
Vibeke Strand et al.
ARTHRITIS CARE & RESEARCH (2019)
Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus
Sarfaraz Hasni et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Lars Ronnblom et al.
LUPUS SCIENCE & MEDICINE (2019)
Discordance of patient and physician health status concerns in systemic lupus erythematosus
V. Golder et al.
LUPUS (2018)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
A. Doria et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus
Ebony Dashiell-Aje et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
Ronald F. van Vollenhoven et al.
LUPUS SCIENCE & MEDICINE (2018)
Patient-reported outcome measures for use in clinical trials of SLE: a review
Zara Izadi et al.
LUPUS SCIENCE & MEDICINE (2018)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod
M. A. Petri et al.
LUPUS (2017)
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art
Chi Chiu Mok
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
Zahi Touma et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
Ioannis Parodis et al.
AUTOIMMUNITY REVIEWS (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
D. J. Wallace et al.
ARTHRITIS CARE & RESEARCH (2016)
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
Andreas Schwarting et al.
RHEUMATOLOGY AND THERAPY (2016)
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
Thomas Doerner et al.
AUTOIMMUNITY REVIEWS (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R. A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE
Herve Devilliers et al.
RHEUMATOLOGY (2015)
Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Katie L. Druce et al.
RHEUMATOLOGY (2015)
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Vibeke Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
Vibeke Strand et al.
RHEUMATOLOGY (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Treatment of Lupus Nephritis With Abatacept
Anca D. Askanase et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Real life experience on the effect of Belimumab in patients with active systemic lupus
Morton Scheinberg et al.
SPRINGERPLUS (2014)
Autoimmune Rheumatic Diseases 3 Immunopathogenic mechanisms of systemic autoimmune disease
Marie Wahren-Herlenius et al.
LANCET (2013)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M. Witt et al.
LUPUS (2013)
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Daniel J. Wallace et al.
RHEUMATOLOGY (2013)
A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials
Denitsa Koynova et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus
Meenakshi Jolly et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2012)
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Efficacy and safety of infliximab in active SLE: a pilot study
S. S. Uppal et al.
LUPUS (2009)
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus
Kathleen McElhone et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Defining clinically meaningful change in health-related quality of life
RD Crosby et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154 - A randomized, double-blind, placebo-controlled trial
KC Kalunian et al.
ARTHRITIS AND RHEUMATISM (2002)
Systemic lupus erythematosus in three ethnic groups.: XI.: Sources of discrepancy in perception of disease activity:: A comparison of physician and patient visual analog scale scores
GS Alarcón et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Endpoints: consensus recommendations from OMERACT IV
V Strand et al.
LUPUS (2000)
分享论文
